BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced that the Company will participate in fireside chats at four upcoming investor conferences:

TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 am ET;
Leerink Global Healthcare Conference on Monday, March 9, 2026 at 11:20 am ET;
Citizens Life Sciences Conference on Tuesday, March 10, 2026 at 9:35 am ET; and
Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 3:00 pm ET

Live webcasts of these events can be accessed from the investors section of the Company's website at https://ir.beonemedicines.com. Archived replays will be available on the Company's website.

About BeOne Medicines

BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before.

To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne's plans, commitments, aspirations and goals related to BeOne's medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled "Risk Factors" in BeOne's most recent periodic report filed with the U.S. Securities and Exchange Commission ("SEC") as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the SEC. All information in this press release is as of the date hereof, and BeOne undertakes no duty to update such information unless required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260217750246/en/

Investor:

Liza Heapes

Tel:+1 857-302-5663

ir@beonemed.com

Media:

Kyle Blankenship

Tel:+1 667-351-5176

media@beonemed.com

BeOne Medicines to Present at Upcoming Investor Conferences